A new self-assessment and benchmarking tool designed specifically for regulators of veterinary medicines has been published in Frontiers, offering national regulatory authorities a structured way to evaluate and compare their own performance.

The tool addresses a gap that has long complicated veterinary regulation: agencies responsible for approving and overseeing animal health products — including drugs and vaccines regulated in the United States by FDA CVM and USDA, and in Europe by the EMA — have lacked a standardized instrument to measure their own regulatory capacity against international peers. Human medicines regulation has benefited from established benchmarking frameworks; veterinary regulation has not.

What the tool does

The published framework walks regulators through a structured evaluation of their own systems. It covers the core functions a veterinary medicines authority must perform: product assessment and registration, quality control, pharmacovigilance and post-market surveillance, inspection and enforcement, and the legal and administrative infrastructure that underpins all of them.

Because the instrument is self-assessment based, it lets agencies in low- and middle-income countries — where regulatory capacity for veterinary products is often thin — identify specific weaknesses without the cost and political friction of external audit. Benchmarking against the same framework then allows agencies, and the international bodies that support them, to track progress over time and prioritize capacity-building investments where gaps are widest.

Why veterinary regulation needs its own instrument

Veterinary medicines regulation differs from human medicines regulation in ways that generic benchmarking tools miss. Regulators must handle companion-animal drugs, food-animal products with residue and withdrawal implications, and veterinary vaccines, including those under USDA jurisdiction in the United States. The assessment framework reflects those species- and product-specific demands rather than importing a human-health template.

Strong veterinary regulatory capacity also carries direct public-health consequences. Food-animal antimicrobials and anthelmintics sit at the intersection of animal welfare, food safety and antimicrobial resistance, and agencies that cannot reliably evaluate or monitor these products weaken more than the livestock supply chain.

Practical implications

For regulators, the immediate value is diagnostic: a repeatable, comparable measure of institutional performance. For stakeholders in animal health — manufacturers seeking registration, veterinarians relying on product quality, and industry depending on predictable review timelines — a widely adopted benchmarking standard could gradually reduce the fragmentation that makes multi-market authorization slow and uneven.

The authors position the tool as a step toward more harmonized international veterinary medicines regulation, with adoption and validation across multiple agencies the logical next phase.